Shots:
- Health Canada has approved Gazyva (obinutuzumab) for adults with active lupus nephritis receiving standard therapy
- Approval was based on P-II (NOBILITY) & P-III (REGENCY) trials, where in REGENCY (n=271), 46.4% on Gazyva + SoC achieved CRR vs 33.1% on SoC. Gazyva’s safety profile was consistent with its well-established profile from haematology-oncology indications
- Gazyva is a Type II engineered humanised anti-CD20 mAb that targets B cells, driving inflammation in lupus nephritis, helping reduce kidney damage, and potentially delaying progression to end-stage kidney disease
Ref: Newswire.CA | Image: Roche | Press Release
Related News: Genentech Reports the US FDA’s Approval of Gazyva (Obinutuzumab) to Treat Lupus Nephritis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
